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A
A.A.M. therapy, children, idiopathic NS (abst) 598
Absorptive method, HD (abst) 644
Acetate-free hemodialysis, IL-6, TNF levels (abst) 642
Acidosis
H-ATPase 31 kD subunit mRNA, CCD 1420
proximal tubular, children, impaired growth (abst) 303
Acquired cystic kidney disease (ACKD)
APKD, flow cytometric DNA ploidy, renal tumors
(abst) 289
hemodialysis patients (abst) 905
renal cell carcinoma (abst) 300
screening 207
ACTH, immune reactive, idiopathic NS, children (abst). . . 588
Actin
in ATP depletion with villin 1828
regulates epithelial Na channels 970
Acute myeloma kidney, Nephrology Forum 1347
Acute renal failure (ARF)
atheroembolic renal disease (abst) 292
calcium antagonist effects (abst) 293
challenges, future trends 50:S-26
children, clinicopathology (abst) 630
dopamine, ANP treatment (abst) 636
elderly, mortality (abst) 292
etiology (abst) 1675
in ICUs, prognostic methods (abst) 1367
in ICUs, treatment/prognosis (abst) 293
idiopathic, in NS (abst) 590
immediate-early genes 1451
neonates, critically ill (abst) 1677
nephrotic syndrome (abst) 591
post-ischemic, EGF (abst) 630
post-ischemic, neutrophil retention, ICAM-1 1584
post-ischemic, thromboxane A2, prostacyclin 1577
primary nephrotic syndrome (abst) 590
rifampicin, due to (abst) 1678
risk factors in (abst) 909
tubular obstruction, synthetic RGD peptide role 1375
Acute renal insufficiency, lupus nephritis (abst) 621
Acute tubular necrosis, experimental, EGF (abst) 631
Adenine nucleotides, PKC, tubular EC wound healing 85
Adenosine triphosphate (ATP)
depletion, actin and villin compartmentation 1828
maleic acid-induced Fanconi syndrome, renal ATPase . 1542
phospholipid hydrolysis in MDCK cells 118
regulates ROMK in distal nephron 1010
Adhesion molecules. See also Intercellular adhesion
molecule-i (ICAM-1)
expression, cytokines, high glucose, MC 51:S-39
in glomerulonephritis (abst) 277
MoAb intervention, anti-MPO crescentic GN (abst). . . 1363
renal changes, IgA nephropathy (abst) 596
in renal disease 1687
T cell expression, HgCl2-induced immune
dysregulation (abst) 1364
VCAM-1, lupus/crescentic nephritis (abst) 597
VCAM-i, lupus nephritis, MPGN (abst) 596
Adrenal cortex cells, lipid content, glycyrrhetic acid
(abst) 614
Adrenergic receptors, renal vascular aiB 1412
Adrenergic transmission parameters, quinapril, ACEi,
EH (abst) 273
Adrenogens, indications for uremic anemia (abst) 283
Adriamycin nephropathy, hyperlipidemia, GS (abst) 594
Adult polycystic kidney disease (APKD)
cardiac features (abst) 276
gene diagnosis methods (abst) 648
mesangial proliferative GN (abst) 1675
Advanced glycosylation end products (AGEs)
detection in dialysis-related amyloidosis 771
diabetic renal and vascular disease 51:S-43
glycated diabetic mesangial matrix changes 517
MC collagen production, PDGF, TGF-13 111
renal function, rats (abst) 627
Afferent arterioles
CsA impairs prorenin-renin conversion (abst) 295
high glucose, Ang II, NOS 683
videomicroscopic responses to Ang I and II (abst) . . . . 1363
Albumin
infusion, steroid-resistant INS, children (abst) 587
i.v. furosemide, diuresis in NS (abst) 1681
riormoalbuminuric IDDM, histological renal changes
(abst) 276
TERaIb, RCalh, albuminuric diabetic rats (abst) 1363
Albumin excretion rate (AER), diurnal variation, IDDM. 1559
Aldosterone, sodium channel permeability in epithelia. . . . 965
Aldosteronism, primary, functional tests (abst) 274
Alkalosis
H-ATPase 31 kD subunit mRNA, CCD 1420
HCO3 flux in CD 52
Allografts. See also Chronic allograft failure; Rejection
cardiac, prolongation with tripchlorolide (abst) . . . . 639, 640
delayed function, secondary HPT (abst) 294
intragraft IL-b mRNA expression 1504
long-term failure 50:S-40
macrophages express thromboxane synthase 1344
soluble serum IL-2r changes (abst) 637, 640
survival, North American children 551
Allopurinol
calcium oxalate calculi (abst) 910
renal ischemia, reperfusion, SOD (abst) 632
Alpha 2-antiplasmin, alpha 2-macroglobulin, children,
NS (abst) 1676
Alpha-adrenoreceptors, Ang gene expression 139
a1-antitrypsin PiZ gene and PR3-ANCA-vasculitis 844
Alport syndrome, carrier detection, X-linked DL-AS . . . . 1891
Aluminum toxicity
diagnosis, treatment (abst) 644
epidemic, HD 469
etiology, diagnosis, treatment (abst) 643
monitoring, HD patients (abst) 1681
Amiloride
binding proteins, topology, Na channels 956
Ca2 transport, convoluted tubule cells 1427
Aminoglycoside toxicity in proximal cells 722
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Amyloidosis
AA type, Behçet's syndrome, NS (abst) 1680
132-m isoforms in amyloid deposits 1397
dialysis-related, AGE detection in 771
systemic, Behçet's syndrome, CRF (abst) 1679
Analgesic nephropathy
diagnosis by CT scan 1316
long-term controlled study, Belgium 1903
Anemia
ACEi, EPO, chronic HD (abst) 287
rHuEPO therapy, CRF (abst) 907
uremia, adrenogen effects (abst) 283
uremic, urea, hemoglobin-oxygen affinity 827
Angiopeptin inhibits intimal proliferation, chronic
allograft dysfunction 52:S-23
Angioplasty, percutaneous transluminal renal, for RVH.. 1927
Angiotensin-converting enzyme (ACE) inhibition
anemia, EPO, chronic HD (abst) 287
endogenous in cardiac and renal tissue (abst) 1366
immune complex nephritis 1778
quinapril, adrenergic transmission, EH (abst) 273
Angiotensin II (Ang II)
activated MAPK cascade, OK cells 1801
afferent/efferent arteriolar responses (abst) 1363
model for AT2-to-AT1 shift 1635
NO, tubuloglomerular feedback responses 1406
renal hemodynamics, glomerular permeability (abst). . . . 299
synthesis, high glucose, afferent arterioles 683
TGF-f3 expression, c-mas oncogene 1818
TGF-/3 regulation, obstructive nephropathy 1233
variation post-renal ischemia (abst) 630
Angiotensin Ii (Ang II) receptors
model for AT2-to-AT1 shift 1635
variation post-renal ischemia (abst) 630
Angiotensinogen (Ang)
gene expression, aipha-adrenoreceptors 139
gene expression, post-renal ischemia (abst) 629
NOS inhibitor, kallikrein gene expression (abst) 631
Anion channels, new role for 994
Anisodamine, transplantation, with dopamine (abst) 638
Anti-endothelial cell antibody (AECA)
assay, IgA nephropathy (abst) 593
lupus nephritis (abst) 622
Anti-myeloperoxidase (MPO) antibodies
crescentic GN, intrarenal LPS injection, rats (abst). . . . 1365
crescentic GN, MoAb intervention, adhesion
molecules (abst) 1363
detection by ELISA (abst) 619
polyarteritis nodosa (PAN) (abst) 619
Anti-neutrophil cytoplasmic autoantibodies (ANCA)
glomerulonephritis, vasculitis (abst) 619
glomerulonephritis (abst) 618
as markers, systemic vasculitis (abst) 278
as markers in HD (abst) 287
PiZ gene of a1-AT and PR3-ANCA-vasculitis 844
renal disease, clinicohistology (abst) 617
Anti-nucleosome antibody binding to cell surface, in vivo
(abst) 1362
Anti-Thy-i monoclonal antibodies induce apoptosis in
MC (abst) 1365
Antibodies
HBV and CMV, HD patients (abst) 1675
HCV, HD patients (abst) 1675
human monoclonal IgG anti-DNA, renal deposits 705
panel reactive lymphocytotoxic, HD (abst) 1676
Anticoagulation, long-term, vascular prosthesis, HD
(abst) 296
Antidiuretic hormone, water transport in amphibian
epithelia 1088
Antigens
CMV antigenemia assay, post-transplant (abst) 639
differentiation, non-neoplastic renal disease, fibrosis
(abst) 277
Fas and BcI-2 expression, GN, apoptosis 1877
HLA distribution, terminal RF (abst) 1675
HLA-DR expression changes, transplantation (abst).... 639
PCNA, renal expression, IgA nephropathy (abst) 591
tubulointerstitial, vascular rejection 52:S-16
Antihypertensive therapy, chronic allograft failure . . . 52:S-107
Antilipidemic therapy. See Lipid-lowering therapy
Antioxidant enzymes, ROS, glomerular injury (abst) 600
Antiphospholipids, HD, lupus anticoagulant, thrombosis .. 794
Antithrombin III, children, NS (abst) 1676
Apoptosis
GN, Fas antigen, Bcl-2 expression 1877
induced by anti-Thy-i MAb in glomerular MC (abst).. 1365
during reperfusion, post-ischemia (abst) 610
SLE nephritis, nucleosomes 666
tubular repair, post-ischemia and reperfusion (abst) . . . . 631
Aquaporin water channels
gene defect, DI (abst) 300
in kidney 1057
Aquaresis by V2 antagonist 220
Area postrema (AP)
mediates renal effects of central All (abst) 611
renal hemodynamics, Na balance, DOCA hypertension
(abst) 613
rHuEPO induced hypertension (abst) 612
Area under the serum creatinine vs. time curve (AUCCr)
predicts rejection 251
Arginine vasopressin (AVP)
aquaresis by V2 antagonist 220
inhibits MAP kinase cascade, MDCK cells 745
V2 receptor defect (abst) 1364
V2 receptor gene mutation expression 554
Arterial pressure
acute/chronic stress, renal function, dietary Na (abst) . . . 612
hypertension, lupus nephritis (abst) 904
Ascorbic acid, megadose, hematuria after (abst) 906
Asphyxia, traumatic, renal injury after (abst) 635
Astragali Acanthopanax Senticosus Harms Mixture
(A.A.M.), children, idiopathic NS (abst) 598
Astragalus (Chinese medicine), effect on cytokines, renal
pathology (abst) 608
Asymptomatic hematuria, renal biopsy, children (abst). . . . 593
Atenolol, renal/systemic hemodynamics with CsA (abst). .1365
Atheroembolic renal disease, ARF (abst) 292
Atherosclerosis, uremia, ultrasonography 820
Atomic force microscopy, visualizing life on
biomembranes 923
Atrial natriuretic factor, renal receptors in
cardiomyopathy 1866
Atrial natriuretic peptide (ANP)
dopamine, ARF (abst) 636
immunolocalization, acute rejection (abst) 909
Autoimmune disease, ANCA as markers 278
Autosomal polycystic kidney disease (APKD)
gender and disease severity, rats 496
recessive, children, prolonged survival (abst) 907
Autosomal recessive nephrogenic DI (abst) 300
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Azathioprine
with CsA, steroids, methotrexate, SLE and LN (abst). . . 623
with CsA and steroids, long-term allograft failure. . . 52:S-94
B
Bact/Alert, Bactec culturing systems, CAPD (abst) 292
Banif criteria
classification, renal transplant biopsy (abst) 910
histologic diagnosis of rejection (abst) 1368
Basic fibroblast growth factor (bFGF)
long-term results in FSGS 1435
MC proliferation, HS proteoglycans inhibit (abst) 1362
upregulates thrombospondin 1 expression, MC 1837
Bcl-2 expression, human GN 1877
Behçet's syndrome
AA type amyloidosis, nephrotic syndrome (abst) 1680
systemic amyloidosis, CRF (abst) 1679
Benazepril, antihypertensive effect, CRF, HD (abst) 1679
f31 integrin in high glucose 51:S-39
132-microglobulin (/32m)
cellular prion glycoprotein clusters, lymphocytes (abst). . 298
cellular prion glycoprotein transport (abst) 298
evaluation by BK-PMMA membrane (abst) 642
isoforms, in healthy persons and amyloid deposits 1397
Betaine metabolism, osmotic regulation 1714
Bicarbonate reabsorption, ontogeny of PT acidification . . 1697
Bicarbonate transport
flux in CD in chloride-depletion alkalosis 52
proximal tubule, hyperfiltration, cell electrolytes 712
proximal tubule Na/H antiporter regulation 1386
Bilharzia and renal failure (abst) 907
Bioelectrical resistance estimates dry-weight (abst) 645
Biomembranes, atomic force microscopy visualization . . . . 923
Biopsy, renal
Banif criteria, clinicopathology (abst) 910
Banif criteria, rejection histology (abst) 1368
children, asymptomatic hematuria (abst) 593
IgA nephropathy, frequency of (abst) 1678
macrophages express thromboxane synthase 1344
sequential, renal structure/function, IDDM 1920
transfemoral with forceps (abst) 275
BK-PMMA membrane, 132MG evaluation (abst) 642
Blood pressure. See also Hypertension
continuous ambulatory monitoring, HD (abst) 274
diurnal variation, IDDM 1559
NG-nitro-L-arginine, renal function, rats (abst) 613
strict control, nephrosclerosis and 851
Bone disease. See Osteodystrophy, renal
Bony oxalate, end-stage renal failure 182
Brush-border membranes, urate-anion exchange,
nicotinate, orotate (abst) 297
Bupleuri Radix (Chinese medicine), proteinuria, MonAb
5-1-6 (abst) 609
C
c-fos and high glucose, PKC role 51:S-12
c-ros expression and metanephric development 1646
C5b-9
IgA nephropathy pathogenesis (abst) 593
urinary, human idiopathic membranous nephropathy .. 1944
Cadmium-induced lEG expression in LLC-PK1 cells 383
Calcifications
tumoral, HD, bone histopathology (abst) 278
vascular, ET, ESRD, secondary HPT (abst) 279
Calciotropic hormones and renal growth 33
Calcitonin
endogenous, secondary HPT, CRF (abst) 280
oral calcitriol, PTH, osteodystrophy (abst) 1677
Calcitriol
low Ca bath controls secondary HPT (abst) 281
oral, PTH, calcitonin, osteodystrophy (abst) 1677
osteodystrophy 657
pulse i.v. vs. oral, secondary HPT, HD (abst) 296
single weekly i.v. bolus, secondary HPT (abst) 278
uremic secondary HPT (abst) 280
Calcium
agents/metabolism, Vit D, children, NS (abst) 590
antagonist, CsA toxicity, Huangqi (Chinese medicine) .. 634
antagonist effects, severe ARF (abst) 293
calcitriol alters PTH-calcium relation (abst) 280
epithelial Ca2-activated K channels 1047
excretion, stone formation, genetic hypercalciuric rats. . 1705
HD concentration, secondary HPT (abst) 281
intracellular, bioactive substances, endothelial cells
(abst) 610
PTH secretion, adynamic renal osteodystrophy 838
PTH secretion, secondary hyperparathyroidism 1553
reducing concentration, HD, vitamin D3 (abst) 280
renal stone formers, hypocitraturia, Na/H antiporter
(abst) 299
serum, modifies set-point, uremia, HD (abst) 280
transport in rabbit distal cells 1102
Calcium (Ca2)
phospholipid hydrolysis, ATP-depleted MDCK cells.... 118
transport, amiloride-stimulated, convoluted tubule cells. 1427
Calcium channel blockers, calcium-phosphate
metabolism, ESRD (abst) 303
Calcium channels
molecular biology of 1111
subunit renal isoforms identified/localized 1097
Calcium oxalate crystals
allopurinol (abst) 910
flow cytometry, urine (abst) 906
monohydrate, stimulate kidney gene expression 501
monohydrate, with MDCK cells 129
nucleation/aggregation, spectrophotometry (abst) 297
urinary prothrombin fragment 1, human urine (abst) . . . 910
Calcium-phosphate metabolism, calcium channel
blockers, ESRD (abst) 303
Calcium signaling
glomerular MC contractile response, DM 51:S-28
impaired in CRF 1324
Calculi, urinary
calcium, hypocitraturia, Nat'H antiporter (abst) 299
calcium excretion, genetic hypercalciuric rats 1705
calcium oxalate, allopurinol (abst) 910
calcium oxalate, prothrombin fragment 1 (abst) 910
early chemistry, circa 1800 876
Cancer
extracutaneous Kaposi sarcoma, post-transplant (abst) . . 301
malignant tumors, post-transplant (abst) 302
renal cell carcinoma, APKD (abst) 300
renal tumors, flow cytometric DNA ploidy, APKD
(abst) 289
Captopril
hemodynamic changes, proteinuria (abst) 275
Rheum (Chinese medicine), CRF progression (abst) .. . 617
test, resistance index, renovascular hypertension 1611
Cardiac abnormalities, APKD and (abst) 276
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Cardiac allograft
failure, antilipidemic therapies and 52:S-57
prolongation with tripchlorolide (abst) 639, 640
Cardiac tissue contains endogenous ACEi (abst) 1366
Cardiomyopathy, renal ANF receptors in 1866
Cardiovascular disease, endothelial function, proteinuria
(abst) 1363
Carnitine
deficiency, dyslipidemia, dialysis (abst) 286
L-carnitine, low i.v. dose, HD (abst) 284
Catheters
dual jugular vein (abst) 286
sepsis, vancomycin (abst) 289
subclavian, jugular, venogram abnormalities (abst) 289
subclavian, Mahurkar dual lumen (abst) 905
urine collection without (abst) 1367
CD4 and CD8, as indicators, acute rejection (abst) 640
CDI4 expression in hemodialysis 1469
CDI 8, PMN interaction with GBM 698
CD4O-CD4OL pathway inhibition prevents murine MGN.. 458
CD62P/CD15s interaction, leukocyte margination, HD 93
Cell electrolytes, PT bicarbonate transport,
hyperfiltration 712
Channel-forming integral protein (CHIP) 1057
Charge selectivity
changes, early pre-eclampsia (abst) 905
testing, nephrotic syndrome (abst) 903
Children
allograft survival, North America 551
ARF, clinicopathology (abst) 630
ARPKD, prolonged survival (abst) 907
asymptomatic hematuria, renal biopsy (abst) 593
fetal ultrasonography, UT abnormalities (abst) 1676
glomerular disease (abst) 587
HBV-associated GN (abst) 627
HBV-MN, idiopathic NS, cellular immunology (abst)... 597
idiopathic NS, immune reactive ACTH (abst) 588
idiopathic NS, i.v. albumin (abst) 587
idiopathic NS, MC proteoglycan synthesis (abst) 300
idiopathic NS, platelet function (abst) 589
impaired growth, proximal tubular acidosis (abst) 303
macrophages in IgA nephropathy 527
nephrotic syndrome (abst) 904
NS, plasma fibrinogen, AT III, alpha 2-MG, alpha 2-
AP (abst) 1676
NS, soluble IL-2 receptor (abst) 598
NS, Vit D, Ca agents/metabolism (abst) 590
RFR alterations, serum creatinine (abst) 1676
UA with disposable napkins, accuracy (abst) 1679
UTI, inactivated uropathogenic bacterial vaccine (abst) . . 1677
UTI with P fimbria (+) E. coli (abst) 1676
Chinese medicine, traditional
A.A.M therapy, children, idiopathic NS (abst) 598
astragalus root, cytokines, renal pathology (abst) 608
Bupleuri Radix, proteinuria, MonAb 5-1-6 (abst) 609
combined, western medicine, lupus nephritis (abst) 624
Epimedium Sagittatum, IL-2 gene expression (abst).... 616
ginsenoside, gentamicin toxicity (abst) 635
gypenoside, renal ischemia (abst) 632
herbs nephropathy, LMW proteinuria 1571
Hirudo, peritoneal phagocytes, renal pathology, CRF
(abst) 615
Huangqi, Ca antagonist, CsA toxicity (abst) 634
protein metabolism, nephrotic patients (abst) 589
Rheum, captopril, CRF progression (abst) 617
rhubarb, glomerular morphology, STZ-diabetic rats
(abst) 627
rhubarb, renal hypertrophy, STZ-diabetic rats (abst). . . . 628
Chlorambucil, membranous nephropathy 1600
Chloride channels
C1C-K2, human kidney 1497
modulators, development of 985
swelling-activated organic osmolyte efflux 994
Chloride depletion alkalosis, HCO3 flux in CD 52
Cholera immunization, immune response deficiency in
IgAN (abst) 1364
Chronic allograft failure
angiopeptin inhibits myointimal proliferation 52:S-23
antihypertensive therapy 52:S-107
azathioprine, CsA and steroids 52:S-94
clinical overview 52:S-2
clinical predictors, rejection 52:S-90
clinical trial design, chronic rejection 52:S-116
clinical trial design, methods to reduce late loss. . . . 52:S-120
dietary protein, RAS, rejection 52:S-102
future directions 52:S-116, 52:S-120
hemodynamic factors, role of 52:S-39, 52:S-43, 52:S-48,
52:S-53
HMG-CoA reductase inhibitors 52:S-1 12
hyperlipidemia, clinical correlation 52:S-61
hyperlipidemia, role in 52:S-57, 52:S-65
hypertension, role in 52:S-48
immune-mediated 52:S-7, 52:S-16, 52:S-19, 52:S-23,
52:S-28, 52:S-34
isoprenoids and Ras, chronic rejection 52:S-34
long-term, drug toxicity and 52:S-68, 52:S-75, 52:S-80






recurrence of original disease 52:S-84
renal mass and late allograft outcome 52:S-43
Chronic renal failure (CRF)
anemia, rHuEPO therapy (abst) 907
Behcet's syndrome, systemic amyloidosis (abst) 1679
benazepril, antihypertensive effects, HD (abst) 1679
endogenous calcitonin, secondary HPT (abst) 280
Hirudo (Chinese medicine), peritoneal phagocytes
(abst) 615
impaired calcium signaling, hepatocytes 1324
insulin releasing response, HD (abst) 617
liver transplant recipients (abst) 293
LV function changes, CAPD (abst) 1679
parathyroid hyperplasia pathogenesis, Nephrology
Forum 259
polyamines in RBC, HD (abst) 615
recombinant EPO, progenitor cells (abst) 282
Rheum (Chinese medicine), captopril (abst) 617
secondary HPT (abst) 617
subclavian vein thrombosis, coagulation profiles (abst) .. 905
urea, hemoglobin-oxygen affinity, anemia 827
Chronic RI, endogenous digitalis-like factor (abst) 648
Cimetidine, GFR estimation, Cockcroft and Gault
formula (abst) 1366
Cimino fistulas, finger pressure measurements 1641
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Cisplatin
critical subcellular targets 761
nephrotoxicity, heme oxygenase 1298
CIC-K2 chloride channel in human kidney 1497
Cockcroft formula, GFR estimation (abst) 1366
Collagen
fibrogenesis, endothelin, CsA (abst) 277
MC production, AGEs, PDGF, TGF-13 111
MC secretion, IGF-1 45
synthesis, MC proliferation, dexamethasone (abst) 606
synthesis, MC proliferation, HrIL-lra (abst) 607
Collagen-I
ET-1, ECM, endothelial/mesangial cells (abst) 606
production, tubular EC, ECM (abst) 647
Collagen-IV
3-D reconstruction, tubular cells, EGF receptor, IL-8
mRNA (abst) 647
a2(IV), a3(IV) mRNA, IgA nephropathy (abst) 602
Collecting ducts
HCO3 flux in alkalosis 52
water channels of 1082
Complement
increased urinary inhibitory activity, LN (abst) 626
inhibition, human MC, TGF-f3 (abst) 606
production, in vitro CMV, human MC (abst) 1365
regulation, anti-GBM nephritis 1728
regulation, rat glomerulus 412
Computed tomography (CT) scan
diagnosing analgesic nephropathy 1316
spiral-CT angiography, renal artery stenosis 1332
Connexins, intercellular channel forming proteins 1148
Continuous ambulatory peritoneal dialysis (CAPD)
adequacy, assessing (abst) 907
adequacy, nutritional assessment (abst) 906
adequacy by plasma iohexol clearance 1985
elderly (abst) 906
exclusion from, causes of definitive (abst) 291
HBV and HCV infections 1680
HCV antibodies, prevalence/risk factors (abst) 291
IL-i levels in dialysate (abst) 642
Kt/V by different estimations of V 563
low-molecular weight proteins in 1937
LV function changes, CRF (abst) 1679
microbiological diagnosis (abst) 292
outcome, diabetic patients (abst) 292
peritoneal equilibrium test (PET) (abst) 1681
peritoneal permeability analysis, standard 866
rifampicin, staphylococcal infection (abst) 296
serum CK and LDH, isoenzymes (abst) 1681
Convoluted tubule cells, amiloride-stimulated Ca2
transport 1427
Cordyceps sinensis (Berk.) Sance., passive Heymann
nephritis 601
Cortical collecting ducts
H-ATPase 31 kD subunit mRNA, acid/base balance... 1420
K channels in basolateral membrane, rats 1036
K secretion through apical K channel 1024
Coumarin, long-term, vascular prosthesis, HD (abst) 296
Creatinine
chronic rejection predicted by AUCC 251
clearance, alternative to, for CAPD adequacy 1985
normal serum, RFR alterations, children (abst) 1676
tubular secretion, ranitidine (abst) 1366
Creatinine kinase, LDH, isoenzymes, CAPD (abst) 1681
Crescentic glomerulonephritis
anti-MPO, MoAb intervention against adhesion
molecules (abst) 1363
anti-MPO antibodies, intrarenal LPS (abst) 1365
IL-i in, Nephrology Forum 576
VCAM-1 expression (abst) 597
Cross-talk
KATP channels in PT 1017
in tight epithelia, Na and K channels 1191
Crushing chest syndrome, renal injury after (abst) 635
Cyclic adenosine monophosphate (cAMP)
differential regulation of IL-6 and IL-8 1767
growth factor, mitogen activated PK, PGE2, MC (abst) . 608
high glucose, PKC activation, fibronectin gene
expression 51:S-3
Cyclic GMP (cGMP)
gated cation channel, renal 1125
natriuretic peptide receptor binding sites (abst) 605
Cyclophosphamide, oral vs. i.v., lupus nephritis (abst) 903
Cyclosporine A (C5A)
azathioprine and steroids with, chronic allograft failure... 52:S-94
diltiazem therapy, serum levels and (abst) 1678
glomerular synthesis of TXB2 (abst) 294
induces collagen fibrogenesis in vitro (abst) 277
ketoconazole with, transplantation (abst) 908
leflunomide with, chronic xenograft lesions 52:S-28
lupus nephritis (abst) 623
lupus nephritis and SLE, combination therapy (abst) ... 623
plasma and urine ET-1, living related donors/recipients
(abst) 300
prolongs cardiac allograft (abst) 640
prorenin-renin conversion, afferent arteriole (abst) 295
refractory NS (abst) 590
steroid resistant idiopathic NS (abst) 277
tertatolol, atenolol, hemodynamic effects (abst) 1365
toxicity, arteriolopathy, rats 431
toxicity, Ca antagonist, Huangqi (Chinese medicine). . . . 634
toxicity, cellular events in 439
toxicity, clinical outcome post-transplant 52:S-80
toxicity, ET cell injury (abst) 634
toxicity, ET supernatant, VSMC, glomerular MC
(abst) 633
toxicity, experimental renal dysfunction 52:S-75
toxicity, modified by oxypurinol (abst) 634
toxicity, modified Mg2 (abst) 635
toxicity, pancreas transplant recipients 489
toxicity, TGF-13 expression 1487
toxicity vs. rejection, differential diagnosis 52:S-68
Cystinosis, nephropathic, in vitro cell lines 536
Cytokines
astragalus root, renal pathology (abst) 608
CAM expression, MC, diabetic nephropathy 51:S-39
ET-1 inhibits iNOS transcription, glomerular MC 1884
intragraft gene expression, allograft rejection and 1504
regulate MCP-1 production, proximal tubular EC 1477
Cytomegalovirus (CMV) infection
antibody prevalence, HD patients (abst) 1675
antigenemia assay, post-transplant (abst) 639
in lupus nephritis (abst) 624
in vitro infection, human MC, complement (abst) 1365
Cytoprotective agents, post-cold ischemia, urine output
(abst) 1680
Cytoxan, gonadal protection with free radical scavengers
(abst) 600
Cytoxic factor, role in glomerulopathy (abst) 598
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D
Dexamethasone, MC proliferation, collagen synthesis
(abst) 606
Diabetes insipidus (DI)
autosomal recessive nephrogenic (abst) 300
intracranial hemorrhage, premature infant (abst) 297
nephrogenic, expression of two AVPR2 mutants 554
Diabetes mellitus
CAPD outcome (abst) 292
renal SPARC mRNA expression 1216
RRT, sixteen-year study (abst) 283
STZ-induced, transgenic mice 51:S-37
TERaIb, RCalh, albuminuric diabetic rats (abst) 1363
transplant recipient management, Nephrology Forum.. 1660
vascular access (abst) 290
Diabetic nephropathy
advanced, without prior adequate control (abst) 282
advanced glycation, renal and vascular disease 51:S-43
c-fos, high glucose, PKC role 51:S-12
Ca signaling, MC contractile response 51:S-28
cytokines, CAM expression, MC 51:S-39
ECM metabolism 51:S-34, 51:S-37, 51:S-39, 51:S-43
endothelins in diabetic kidneys 51:S-45
GH expression and diabetic GS, mice 51:S-37
glycated mesangial matrix changes 517
lovastatin, TGF-131 mRNA expression 51:S-61
mesangial PLA2 activity 51:S-22
microvascular factors 51 :S-45, 51 :S-50, 51 :S-61
nitric oxide role in 51:S-50
oxidative stress and 51:S-18
PKC activation, fibronectin gene expression 51:S-3
rhubarb (Chinese medicine), glomerular morphology
(abst) 627
rhubarb (Chinese medicine), renal hypertrophy (abst) . . 628
signal transduction. 51:S-3, 51:S-12, 51:S-18, 51:S-22, 51:S-28
TGF-j3, GS, renal hypertrophy 51:S-34
tubular interstitium alterations (abst) 629
urinary microproteins (abst) 628
Dialysate
IL-i levels, CAPD (abst) 642
low Ca, PTH, secondary HPT (abst) 278
low sodium peritoneal 1950
pyruvate neutralizes cytotoxicity 177
temperature, central hemodynamics, urea kinetics 237
Dialysis. See also Continuous ambulatory peritoneal
dialysis; Hemodialysis
accuracy of urea removal 785
amyloidosis, AGE detection in 771
current status, challenges, limitations 50:S-37
dyslipidemia, carnitine deficiency (abst) 286
evaluating patients for selection (abst) 907
high-flux, post-dialysis solute rebound (abst) 284
low-dose strategy for EPO (abst) 908
predialysis HCV, Spain (abst) 282
predialysis nutritional assessment, IGF-1 (abst) 281
renal tumors (abst) 288
urea/solute rebound (abst) 284, 285
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hemophan, clinical experience (abst) 645
scanning force microscopy, membrane inner surface
(abst) 296
in vitro IL-i production (abst) 641
Diastolic dysfunction, EH, hyperinsulinemia (abst) 274
Diet
IGF-i and IGFBPs mRNA, GH deficiency 65
L-Arg supplementation in remnant glomerulus 1848
nutritional assessment, anti-HCV positive patients, HD
(abst) 286
nutritional assessment, CAPD, adequacy of dialysis
(abst) 906
nutritional assessment, dyslipidemia, carnitine
deficiency, dialysis (abst) 286
protein intake, IGF-1, PTH-related renal growth 33
protein intake, RAS in chronic allograft failure. . . . 52:S-102
salt intake, post-ischemic kidney regeneration (abst). . . . 631
salt intake, stress, arterial pressure, renal function
(abst) 612
Diffuse-esophageal leiomyomatosis, X-linked Alport
syndrome 1891
Digitalis-like factor, endogenous, in CR1, NS, chronic
GN (abst) 648
Diltiazem
calcium-phosphate metabolism, ESRD (abst) 303
CsA serum levels, post-transplant (abst) 1678
Dipeptidyl aminopeptidase IV (DAP IV) in renal disease
(abst) 646
Diurnal variation in SI, AER and BP in IDDM 1559
DNA
flow cytometric analysis, renal tumors, APKD (abst). . . . 289
synthesis dissociated from lEG, post-ischemia 1451
Donor kidneys
attitudes towards, S. Africa (abst) 909
cadaveric, allocation (abst) 301
cadaveric, case review/analysis (abst) 641
cadaveric, functioning over 20 years (abst) 301
cadaveric, procurement, S. Africa (abst) 909
CsA effect on plasma/urine ET-1 (abst) 300
living non-related, Switzerland (abst) 295
living unrelated in India, risks/ethics of (abst) 1679
reduced renal mass, long-term effects 814
Dopamine
with ANP for ARF (abst) 636
renal mobilization, Na loading, essential hypertension
(abst) 609
transplantation, with anisodamine (abst) 638
Drug toxicity. See Nephrotoxicity
Dry-weight estimation, bioelectrical resistanace
measurement (abst) 645
Dyslipidemia, carnitine deficiency, dialysis (abst) 286
Dyspepsia, uremia, helicobacter pylon antibodies (abst). . 1677
E
Efferent arterioles, videomicroscopic responses to Ang I
and II (abst) 1363
Elderly
ARF mortality (abst) 292
CAPD (abst) 906
ECG monitoring during HD (abst) 643
renal disease, clinicopathology (abst) 595
renovascular disease, beginning dialysis 171
Electrocardiogram (ECG) monitoring, elderly on HD
(abst) 643
Electrolytes, cell, PT bicarbonate transport,
hyperfiltration 712
Electron spin resonance spectroscopy, detects oxidants in
uremic plasma 199
1 113-hydroxysteroid dehydrogenase (OHSD)
furosemide inhibits (abst) 298
post-uninephrectomy (abst) 297
ELISA, glutathione transferases, quantitation in urine. . . 570
Embolism, pulmonary, as complication of NS (abst) 587
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inhibits fibronectin production, MC (abst) 607
inhibits MC proliferation/cell cycle (abst) 604
Enalapril, post-transplant erythrocytosis (abst) 293, 1678
End-stage renal disease (ESRD)
bony content of oxalate 182
calcium-phosphate metabolism, calcium channel
blockers (abst) 303
care of patients with 50:S-7
ET, secondary HPT, vascular calcifications (abst) 279
future trends 50:S-3
Endogenous digitalis-like factor, CR!, NS, chronic GN
(abst) 648
Endothelial cells
collagen-I, ET-1, ECM, MC proliferation (abst) 606
complement regulation, rat glomerulus 412
CsA-induced injury (abst) 634
CsA nephropathy, VSMC, glomerular MC (abst) 633
dysfunction, IgA nephropathy (abst) 275
glomerular, MCP-1 production 1857
glomerular injury, TNF-a, LPS (abst) 302
heparin-induced vascular relaxation 1508
impaired function, nephrotic range proteinuria 544
impaired function, nephrotic range proteinuria (abst) . . 1363
intracellular Ca, bioactive substances (abst) 610
Endothelin-1 (ET-1)
collagen-I, ECM, endothelial/mesangial cells (abst) 606
CsA, living related donors/recipients (abst) 300
HrIL-10 inhibits MC proliferation (abst) 607
inhibits iNOS transcription, glomerular MC 1884
MC inflammatory effects (abst) 604
mediates tubular regeneration 390
niesangial proliferative nephritis, rats 1290
physiologic changes, uninephrectomy, humans (abst) . . . 303
production, tubular EC, ECM (abst) 647
production in LLC-PKI cells, ECM (abst) 646
renal diseases and (abst) 903
Endothelin (ET)
cultured human MC express ET, ETr genes (abst) 603
diabetic nephropathy 51:S-45
ESRD, secondary HPT, vascular calcifications (abst) . . . 279
role in 2k2c hypertension (abst) 613
in vitro induction collagen fibrogenesis (abst) 277
Epidermal growth factor (EGF)
AVP inhibits MAP kinase cascade, MDCK cells 745
receptor, 3-D reconstruction, tubular cells, collagen-
IV, IL-8 mRNA (abst) 647
renal ischemia, ARE (abst) 630
toxic acute tubular necrosis (abst) 631
Epimedium Sagittatum (Chinese medicine), IL-2 gene
expression (abst) 616
Epithelial cells
COM crystals stimulate gene expression 501
glonierular, manganese SOD regulation 354
glomerular, PBMC effects (abst) 599
iNOS, NF-KB and transcriptional control 674
mitogen activated protein kinase, IGF-I, Pi transport
(abst) 299
tubular, adenine nucleotides and renal wound healing ... 85
tubular, cytokine-mediated MCP-1 regulation 1477
tubular, fibronectin synthesis 1810
tubular, nephropathic cystinosis, cell lines 536
Erythrocytosis
post-transplant, enalapril treatment (abst) 1678
Erythrocytosis, post-transplant, enalapril (abst) 293
Erythropoietin (EPO). See also Recombinant human
erythropoietin
ACEi worsens anemia, chronic HD (abst) 287
adrenogens for uremic anemia (abst) 283
ferropenia, high ferritin levels (abst) 282
low-dose strategy, dialysis (abst) 908
serum levels in SLE (abst) 625
Escherichia coli, P fimbria, childhood UTI (abst) 1676
Essential hypertension (EH)
altered Na transport, LVH, body mass (abst) 273
altered Na transport, metabolic alterations (abst) 273
diastolic dysfunction, hyperinsulinemia (abst) 274
Na loading, renal mobilization of dopamine (abst) 609
quinapril, ACEi, adrenergic transmission parameters
(abst) 273
resistance index after captopril 1611
Extracellular matrix (ECM)
accumulation, gentamicin toxicity, ginsenoside
(Chinese medicine) (abst) 635
ACEi, immune complex nephritis 1778
ET-1 production in tubular cells (abst) 646
ET-1 production in tubular EC, collagen I (abst) 647
metabolism, diabetic nephropathy . 51:S-34, 51:S-37, 51:S-39,
51:S-43
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Extracorporeal solute clearance, blood vs. dialysate (abst) . . . 285
F
Familiar aggregation, HLA system, Na transport,
hypertension (abst) 273
Fanconi syndrome, maleic acid-induced 1542
Fas antigen expression, human GN 1877
Felodipine, calcium-phosphate metabolism, ESRD (abst).. 303
Ferropenia, high ferritin levels, EPO (abst) 282
Fibrillaty glomerulopathy, clinicopathology (abst) 595
Fibroblast heterogeneity, renal 50:S-33
Fibronectin
emodin inhibits MC production (abst) 607
gene expression, PKC, cAMP, diabetic nephropathy. . 5 l:S-3
glomerular MC phagocytosis (abst) 605
glomerulopathy, familial aspects 163
opsonin receptor expression, PMC, uremia (abst) 615
synthesis, thromboxane, PKC, TGF-f3, MC 422
synthesis in tubular EC 1810
Fistulas, Cimino, finger pressure measurements 1641
FK506
allograft rejection, preliminary experience (abst) 908
glomerular hemodynamics, mesangial cells 56
Flaxseed in lupus nephritis 475
Fleroxacin, pharmacokinetics, multiple dosing, HD (abst) . 297
Flow cytometry
DNA ploidy, renal tumors, APKD (abst) 289
urine, calcium oxalate crystallization (abst) 906
Fludrocortisone treatment, hyperkalemia (abst) 289
Focal segmental glomerulosclerosis (FSGS)
HCV prevalence, GN (abst) 276
long-term FGF-2 results in 1435
Free radicals,- cytoxan-induced gonadal damage, rats (abst). . 600
Furosemide
inhibits 11f3-OHSD (abst) 298
iv., albumin, diuresis in NS (abst) 1681
G
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Gated K channels 1031






Gault formula, GFR estimation (abst) 1366 anti-GBM, complement regulator 1728
Genetics anti-GBM, macrophage proliferation 753
cultured human MC express ET, ETr genes (abst) 603 CD18 in PMN interaction with GBM, TNF-cx 698
cultured human MC express foreign gene (abst) 603 chronic, endogenous digitalis-like factor (abst) 648
diagnosis methods, adult PKD (abst) 648 crescentic, IL-i, Nephrology Forum 576
expression of two AVPR2 mutants 554 Fas antigen and Bcl-2 expression, apoptosis 1877
fibronectin deposits, glomerulopathy 163 hepatitis B-associated (abst) 903
HLA-DR, -DO gene frequencies, IgA nephropathy hepatitis B virus (abst) 626, 627
(abst) 603 hepatitis C prevalence (abst) 276
HLA-DR polymorphism, idiopathic NS (abst) 588 hepatitis C virus (abst) 626
ion channel cross-talk, tight epithelia 1191 ICAM-1, TNF-a, humans (abst) 596
ion channel diseases and 1180 infantile purpura, treatment (abst) 618
ion channel function, phosphorylation and 1167 membranoproliferative, ICAM-1, VCAM-1 expression
ion channel regulation, MDCK cells 1200 (abst) 596
ion channel regulation by GF 1158 membranous, CD4O-CD4OL pathway inhibition,
PiZ gene of a1-AT and PR3-ANCA-vasculitis 844 murine 458
RAS polymorphisms with microalbuminuria in membranous, HCV-Ab incidence (abst) 276
NIDDM 1898 mesangial proliferative, adult PKD and (abst) 1675
renal SPARC mRNA, diabetes 1216 mesangial proliferative, clinicopathology (abst) 595
Gentamicin toxicity mesangial proliferative, IgA/non-IgA, AECA assay
ginsenoside (Chinese medicine), ECM 635 (abst) 593
multiprotein-zine protects (abst) 635 murine, lupus-like, PAl-i induction 1459
Ginsenoside (Chinese medicine), gentamicin toxicity murine, lupus-like, PAl-I induction (abst) 304
(abst) 635 oxidative stress-inducible PTPase 1911
Glomerular basement membrane (GBM) pathogenesis, MCP-1 in ET cells 1857
anti-GBM nephritis, complement regulator 1728 primary mesangiocapillary, leukocytes (abst) 908
anti-GBM nephritis, macrophage proliferation 753 rapidly progressive, triple therapy (abst) 1678
CDI8 in PMN interaction with 698 Spain, 1993 data (abst) 275
changes, early onset pre-eclampsia (abst) 904 Glomeruloscierosis (GS)
HS prevents immune complex binding, nephritis (abst). 1362 DM, growth hormone expression, mice 51:S-37
Glomerular disease DM, TGF-p, renal hypertrophy 5 1:S-34
children, diagnosis of (abst) 587 endogenous hyperlipidemia, adriamycin nephropathy
cytoxic factor role (abst) 598 (abst) 594
fibrillaty glomerulopathy, clinicopathology (abst) 595 FSGS, HCV prevalence in GN (abst) 276
fibronectin deposits, familial aspects 163 FSGS, long-term FGF-2 results in 1435
membranous glomerulopathy, HBV-associated (abst)... 626 HI V-associated 311
primary, frequency of IgA nephropathy (abst) 1678 transgenic rescue of mouse GS 80
therapeutic approaches, limitations of 50:S-19 Glomerulus
Glomerular filtration rate (GFR) Ca signaling, MC contractile response, DM 5 i:S-28
cimetidine, Cockcroft and Gault formula (abst) 1366 complement regulation, rats 412
evaluation with SPECT (abst) 609 remnant, L-arginine limits proliferation 1848
NO regulates (abst) 303 transfer of mutated gene encoding TGF-13 1747
renal morphology, IDDM (abst) 276 Glucocorticoids
residual, urea rebound, Kt/V (abst) 285 mechanisms, ROS-mediated glomerular injury (abst) ... 600
Glomerular function receptors, passive Heymann nephritis (abst) 601
nitric oxide actions 20 Glucose, high
permeability, renal hemodynamics, Ang II (abst) 299 adhesion molecule expression, cytokines, MC 51:S-39
Glomerular hematuria, treatment with ligustrazine (abst). . 594 afferent arterioles, Ang II, NOS 683
Glomerular hemodynamics c-fos, PKC role, diabetic nephropathy 51:S-12
FK506, mesangial cells 56 mesangial PLA2 activity 51:S-22
o-3 fatty acids 1792 PKC activation, fibronectin gene expression, cAMP .. 51:S-3
pregnancy, renal ablation in rats 39 TGF-/3, MC, isolated glomeruli (abst) 629
Glomerular injury TGF-13, MC, MvlLu (abst) 628
ACEi, immune complex nephritis 1778 Glucose polymer improves ultrafiltration in CCPD (abst). 1368
antibody-mediated, modulated by IL-ira, soluble IL- Glutathione
ir, TNFr myohemoglobinuric PT injury 1624
IL-i, ROS, glomerular macrophages (abst) transferases, ELISA quantitation, urine 570
macrophages in anti-GBM GN Glycation
ROS-mediated, prevention/treatment advanced in DM 51:S-43
Glomerular morphology, 3-D analysis, subtotal mesangial matrix changes, DM 517
nephrectomy Glycine phospholipid hydrolysis in MDCK cells 118
Glomerulonephritis (GN) Glycoproteins
adhesion molecules in (abst) 277 PrPC, cellular, clusters, 2m, lymphocytes (abst) 298
ANCA demonstrated positive (abst) 618 PrPC, cellular, transport, 132m (abst) 298
ANCA significance (abst) 619 Glycyrrhetic acid, lipids, adrenal cortex cells (abst) 614
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Growth factors
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mitogen activated PK, cAMP, PGE2, MC (abst) 608
regulate mesangial ion channels 1158
Growth hormone
deficiency, nutrition, IGF-2, IGFBPs mRNA 65
expression, diabetic GS, mice 51:S-37
IGF-1 and the kidney 321
renal osteodystrophy 657
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aldosterone modulation, Na permeability in epithelia. . 965
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H
H-ATPase, acid/base balance, collecting duct cells 1420
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Helicobacter pylon antibodies, uremic dyspepsia (abst) . . 1677
Hematuria
asymptomatic, children, renal biopsy (abst) 593
glomerular, treatment with ligustrazine (abst) 594
megadose ascorbic acid (abst) 906
Heme oxygenase
myohemoglobinuric PT injury 1624
toxic renal injury, cisplatin 1298
Hemodialysis. See also Vascular access
ACEi worsens anemia, EPO (abst) 287
acetate-free, IL-6, TNF levels (abst) 642
acquired cystic kidney disease (abst) 905
aluminum toxicity, endemic 469
aluminum toxicity (abst), 643, 644 1681
ANCA as immunologic markers (abst) 287
antiphospholipids, lupus anticoagulant, thrombosis 794
benazepril, antihypertensive effects, CRF (abst) 1679
CD14 expression in 1469
CD62P/CD15s interaction, leukocyte margination 93
changes, lymphocyte screening function (abst) 641
chronic, RRF (abst) 286
chronic adult, hepatic markers (abst) 1680
continuous ambulatory BP, hypertension (abst) 274
dose and on-line urea monitor (abst) 288
ECG monitoring, elderly (abst) 643
extracorporeal solute clearance, blood vs. dialysate
(abst) 285
HBV, fulminant, common-source outbreak 1963
HBV and CMV antibody prevalence (abst) 1675
HBV and HCV genome in PBMC 1958
HBV and HCV infections (abst) 1680
HCV, isolation effectiveness (abst) 286, 288, 289
HCV antibody prevalence (abst) 1675
HCV hepatopathy (abst) 290
HCV 1gM anti-core antibodies, HD (abst) 284
HCV patients, isolation measures (abst) 288
HCV positive, nutritional status (abst) 286
HCV prevalence (abst) 290
HCV prevalence and isolation (abst) 286
HCV transmission (abst) 288
hemophan dialyzers, clinical experience (abst) 645
heparin-free absorptive method (abst) 644
hepatitis infection, serological study (abst) 643
hypertriglyceridemia, LMW-heparin (abst) 287
hypoalbuminemia 510
IL-2 gene expression (abst) 648
inactive plasma renin activity (abst) 642
insulin releasing response, CRF (abst) 617
i.v. iron therapy (abst) 908
L-carnitine, low i.v. dose (abst) 284
membranes, BK-PMMA, 132m evaluation (abst) 642
membranes, plasma protein adsorption 481
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surface (abst) 296
multiple dosing fieroxacin, pharmacokinetics (abst) 297
neoplastic disease and (abst) 291
panel reactive lymphocytotoxic antibodies (abst) 1676
polyamines in RBC, CRF (abst) 615
predialysis IGF-1, nutrition (abst) 281
pulse i.v. vs. oral calcitriol, secondary HPT (abst) 296
recombinant hirudin, compared to heparin 1338
reducing Ca concentration, vitamin D3 (abst) 280
regional bone density evaluation, osteodystrophy (abst) . . 1680
serum Ca modifies set-point in uremia (abst) 280
thrice vs. once weekly rHuEPO (abst) 296
tumoral calcifications, bone histopathology (abst) 278
urea reduction rate measures adequacy (abst) 287
Hemodynamics. See also Renal hemodynamics
central, dialysate temperature, urea kinetics 237
chronic allograft failure, factors in 52:S-39, 52:S-43,
52:S-48, 52:S-53
finger pressure measurements, Cimino fistulas 1641
PD solutions reverse hemodynamic effects of NOSi . . . 1977
tertatolol and atenolol, CsA, post-transplant (abst). . . . 1365
Hemofiltration in human sepsis 1563
Hemoglobin carbamylation in RE 1605
Hemoglobin-oxygen affinity, urea, uremic anemia 827
Hemolytic uremic syndrome (HUS) 2
Hemophan dialyzers, clinical experience (abst) 645
Hemorrhage, intracranial, premature infant, transient DI
(abst) 297
Hemorrhagic fever with renal syndrome (HFRS)
renal interstitial lymphocyte subset changes (abst) 619
ultrastructure features (abst) 637
Henoch-SchOnlein purpura, triple therapy, RPGN (abst) . 1678
Heparan sulfate
proteoglycans inhibit MC proliferation, bFGF (abst). . . 1362
Heparan sulfate, immune complex binding to GBM,
nephritis (abst) 1362
Heparin
compared to recombinant hirudin, HD 1338
induced vascular relaxation 1508
low-molecular weight, hypertniglyceridemia, HD (abst). . 287
Heparin-free HD (abst) 644
Hepatic markers, chronic adult HD patients (abst) 1680
Hepatitis B virus (HBV)
antibody prevalence, HD patients (abst) 1675
atypical membranous glomerulopathy (abst) 626
fulminant, in HD patients 1963
genome in PBMC, HD patients 1958
glomerulonephritis, adults and children (abst) 627
glomerulonephritis (abst) 903
HCV reduces HBV vaccine response (abst) 283
HD and CAPD patients (abst) 1680
IgA nephropathy, relationship to 592
infection, HD patients (abst) 643
membranous nephropathy, children, cellular
immunology (abst) 597
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Hepatitis C virus (HCV)
antibodies, isolation effectiveness, HD (abst) 286, 288
antibodies, nutritional status, HD (abst) 286
antibodies in glomerular pathology (abst) 276
antibody prevalence, HD patients (abst) 1675
antibody prevalence/risk factors, CAPD (abst) 291
genome in PBMC, HD patients 1958
glomerulonephritis and 626
HD and CAPD patients (abst) 1680
hepatopathy, HD (abst) 290
1gM anti-core antibodies, HD (abst) 284
infection, HD patients (abst) 643
isolation effectiveness, HD (abst) 289
predialysis prevalence, Spain (abst) 282
prevalence in dialysis centers (abst) 290
reduces HBV vaccine response (abst) 283
transmission, HD (abst) 288
Herbal medicine. See Chinese medicine, traditional
Heredity. See Genetics
Heroin addiction, renal function in (abst) 620
I-Ieymann nephritis
passive, Cordyceps sinensis (Berk.) Sance 601
passive, glucocorticoid receptors (abst) 601
High-flux hemodialysis, post-dialysis solute rebound
(abst) 284
Hippurate clearance, drug-induced changes, measures
RBF 1617
Hirudin, recombinant, compared to heparin, HD 1338
Hirudo (Chinese medicine), peritoneal phagocytes, CRF
(abst) 615
HLA distribution, terminal RF (abst) 1675
HLA-DR antigen expression changes, post-transplant
(abst) 639
HLA-DR gene frequency
idiopathic nephrotic syndrome (abst) 588
IgA nephropathy (abst) 603
lupus nephritis (abst) 625
HLA typing
familiar aggregation, altered Na transport,
hypertension (abst) 273
transplantation (abst) 295
Wegener's granulomatosis and HLA-DR13DR6 801
HMG-CoA reductase
gene expression, puromycin-induced nephrosis 1970
inhibitors, solid organ transplantation 52:S-112
inhibitors, TGF-J31 mRNA, diabetic nephropathy... 51:S-61
Huangqi (Chinese medicine), Ca antagonist, CsA toxicity
(abst) 634
Human immunodeficiency virus (HIV)
glomerulosclerosis and 311
steroid-responsive nephropathy (abst) 1366
Hydroxyl radical, glomerular injury, IL-i (abst) 599
Hypercalciuria
familial hypomagnesemia, nephrocalcinosis (abst) 274
stone formation, Ca excretion, rats 1705
Hypercholesterolemia, LDL-apheresis treatment (abst) . . . 282
Hyperfiltration, PT bicarbonate transport, cell
electrolytes 712
Hyperinsulinemia, EH, diastolic dysfunction (abst) 274
Hyperkalemia, fludrocortisone treatment (abst) 289
Hyperlipidemia
adriamycin nephropathy, GS (abst) 594
antilipidemic therapies, chronic rejection 52:S-65
antilipidemic therapies, HMG-CoA reductase
inhibitors 52:S-112
chronic allograft failure, role in 52:S-57
clinical correlation, chronic allograft failure 52:S-61
endogenous, adriamycin nephropathy, GS (abst) 594
post-transplant, epidemiology (abst) 294
post-transplant (abst) 294
simvastatin, diet, idiopathic membranous nephropathy
(abst) 904
Hyperoxaluria
COM crystals, kidney gene expression 501
primary, bony content of oxalate, ESRD 182
primary, clinical manifestations (abst) 297
Hyperparathyroidism. See Secondary
hyperparathyroidism
Hypertension. See also Essential hypertension
2k2c model, ET role (abst) 613
antihypertensives and chronic allograft failure 52:S-107
arterial, renal function, epidemiology study (abst) 274
arterial, with lupus nephritis (abst) 904
benazepril, CRF, HD (abst) 1679
BP and progression of nephrosclerosis 851
CABP monitoring, HD (abst) 274
chronic allograft dysfunction, role in 52:S-48
DOCA induced, area postrema, renal hemodynamics,
Na balance (abst) 613
HLA familiar aggregation, altered Na transport (abst) . . 273
nephrosclerosis, prognosis (abst) 273
post-transplant, chronic allograft failure 52:S-39
renal damage induces, NO synthesis blockage (abst). . . . 611
renovascular, treatment with balloon-expandable stent
(abst) 1368
renovascular, treatment with PTRA 1927
rHuEPO, vascular responsiveness, RF 806
rHuEPO induced, area postrema function (abst) 612
rHuEPO induced, mechanisms of (abst) 611
treatment and prevention 50:S-14
Hypertriglyceridemia
lipoprotein lipase activity, RF 779
low molecular weight heparin, HD (abst) 287
Hypoalbuminemia, mechanisms in HD 510




Hypothalamic-pituitary-thyroid axis, uremia (abst) 1678
I
Idiopathic acute renal failure in NS (abst) 590
Idiopathic calcium nephrolithiasis, renal and red cell
oxalate 1549
Idiopathic membranous nephropathy, simvastatin, diet,
hyperlipidemia (abst) 904
Idiopathic nephrotic syndrome
children, cellular immunology, A.A.M. therapy (abst). . . 598
children, cellular immunology (abst) 597
children, immune reactive ACTH (abst) 588
children, MC proteoglycan synthesis (abst) 300
children, platelet function (abst) 589
HLA-DR gene polymorphism (abst) 588
PBMC detect IL-i mRNA expression (abst) 602
steroid-resistant, children, i.v. albumin (abst) 587
steroid-resistant, CsA (abst) 277
steroid-resistant, sequential immunosuppression (abst) . . 294
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anti-endothelial cell antibody assay (abst)
cellular adhesion molecule, renal changes (abst)
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endothelial dysfunction markers (abst)
hepatitis B virus and (abst)
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immune response deficiency, cholera immunization
(abst) 1364
natural course GN and PDGF, TGF-p 1530
pathogenesis and C5b-9 (abst) 593
primary, immunogenetic aspects 1989
renal biopsy, serum Ig levels (abst) 1678
renal expression of PCNA (abst) 591
serum IgA-FN aggregate levels (abst) 592
IgG anti-DNA antibodies, human monoclonal, renal
deposits 705
Immediate-early gene (lEG) expression
DNA synthesis dissociated, post-ischemia 1451
LLC-PK1 cells, cadmium-induced 383
Immune complex nephritis
ACE inhibition 1778
HS prevents immune complex binding to GBM (abst) . 1362
Immune functions
BSA nephritis (abst) 609
children, idiopathic NS, A.A.M. therapy (abst) 598
children, idiopathic NS, HBV-MN (abst) 597
deficient in IgAN after cholera immunization (abst) . . . 1364
HgC12-induced dysregulation, T cell adhesion molecule
expression (abst) 1364
RBC deficiency, rHuEPO, uremia (abst) 616
Immune-mediated chronic allograft failure
angiopeptin, myointimal proliferation inhibition .... 52:S-23
isoprenoids and Ras 52:S-34
lefiunomide, CsA, xenograft lesions 52:S-28
molecular mechanisms 52:S-7
mycophenolate mofetil 52:S-19
tissue antigens, tubulointerstitial/vascular rejection . . 52:S-16
Immunogenetic aspects, primary IgA nephropathy 1989
Immunoglobulins (Ig)
light chains, myeloma tubulopathies 72
serum levels, IgA nephropathy (abst) 1678
Immunosuppression
extracutaneous Kaposi sarcoma, post-transplant (abst) . . 301
HMG-CoA reductase inhibitors, post-transplant ... 52:S-112
mycophenolate mofetil 52:S-19
mycophenolate mofetil, transplantation 52:S-98
sequential, steroid-resistant NS (abst) 294
Infantile purpura glomerulonephritis, thymus immuno-
suppressor essence (abst) 618
Infection
CAPD, microbiological diagnosis (abst) 292
catheter-related, vancomycin (abst) 289
human sepsis in hemofiltration 1563
staphylococcal, CAPD, rifampicin (abst) 296
UTI, screening with routine UA (abst) 300
Injury, renal. See also Ischemia, renal
acute radiation sickness (abst) 636
complement regulator in anti-GBM nephritis 1728
glomerular, modulated by ILr and TNFr 1738
glomerular, ROS-mediated (abst) 600
glomerular endothelial, LPS, TNF-cs (abst) 302
glomerular macrophages, IL-i, ROS (abst) 599
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cellular, transport, f32m (abst) 298
Proliferating cell nuclear antigen, renal expression, IgA
nephropathy (abst) 591
Prorenin, plasma, CsA impairs conversion (abst) 295
Prostacyclin, post-ischemic ARF, thromboxane A2 1577
Protease resistance, Ig light chains, myeloma
tubulopathies 72
Protein adsorption, HD membranes 481
Protein/creatinine ratio, urinary, quantitation of
proteinuria (abst) 302
Protein intake
IGF-1, PTH-related renal growth 33
RAS in chronic allograft failure 52:S-102
Protein kinase C (PKC)
activation, Na/K-ATPase in PCT, rats (abst) 299
adenine nucleotides, renal tubular EC healing 85
fibronectin gene expression, cAMP, diabetic
nephropathy 51:S-3
high glucose and c-fos, PKC role 51:S-12
parallel inhibitory signaling, TGF-p and PMA 738
thromboxane, fibronectin, TGF-/3, MC 422
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Protein kinases
AVP inhibits MAP kinase cascade, EGF, MDCK cells.. 745
MAPK, growth factor, cAMP, PGE2, MC (abst) 608
MAPK, Pi transport, IGF-1, EC (abst) 299
Protein metabolism, nephrotic patients, Chinese herbs
(abst) 589
Protein phosphatases I and 2A, early nephrogenesis 103
Protein phosphorylation of ion channels 1167
Protein tyrosine phosphatase (PTPase), oxidative stress-
inducible, GN 1911
Proteins
intercellular channel forming, connexins 1148
LMWP in CAPD 1937
urinary, early diabetic nephropathy (abst) 628
urinary, SDS PAGE predicts steroid responsiveness,
NS (abst) 904
Proteinuria
accuracy of urinary protein/creatinine ratio (abst) 302
ACEi, immune complex nephritis 1778
captopril, hemodynamic changes (abst) 275
Chinese herb nephropathy 1571
Chinese medicine Bupleuri Radix, MonAb 5-1-6 (abst). . 609
early onset pre-eclampsia, histology (abst) 905
human monoclonal IgG anti-DNA antibodies, SCID. . . . 705
impaired endothelial function, NO release 544
nephrotic range, impaired endothelial function (abst),
1363
urinary microproteins, diabetic nephropathy (abst) 628
Proteoglycan synthesis
mesangial cells, idiopathic NS, children (abst) 300
mesangial cells, rats in vitro 1278
Proximal tubular cells
aminoglycoside toxicity 722
cisplatin, critical subcellular targets 761
cytokine-mediated MCP-1 regulation 1477
nephropathic cystinosis, cell lines 536
proliferation, IL-8, ATPase (abst) 646
Proximal tubules
cross-talk and KATP channels 1017
function in neonates, urinary retinolbinding protein
(abst) 645
H transport, hyperfiltration, cell electrolytes 712
IFN-y independent upregulation, MHC II 1721
mild renal acidosis, children, impaired growth (abst). . . . 303
myohemoglobinuric injury 1624
Na/H antiporter regulation 1386
NHE-3 expression, rat kidney 1206
ontogeny of acidification 1697
PKC activation, Na/K-ATPase (abst) 299
TGF-p expression, Ang II, cmas oncogene 1818
Pulmonary embolism, as complication of NS (abst) 587
Puromycin-induced nephrosis, hepatic HMG-CoA
reductase gene expression 1970
Pyruvate neutralizes peritoneal dialysate cytotoxicity 177
Q
Quinapril, ACEi, adrenergic transmission, EH (abst) 273
R
Radiation sickness, acute, renal damage during (abst) . . . . 636
Radiopharmaceuticals determine renal functional reserve
(abst) 906
Ranitidine, tubular creatinine secretion (abst) 1366
Rapidly progressive glomerulonephritis, triple therapy,
Henoch-Schonlein (abst) 1678
Ras protein, role in chronic rejection, isoprenoids . . . . 52:S-34
Reactive oxygen species, glomerular injury, IL-I (abst). . . . 599
Recombinant human erythropoietin (rHuEPO)
anemia of CRF (abst) 907
induces hypertension, area postrema function (abst). . . . 612
mechanism related to hypertension (abst) 611
once weekly subcutaneous, HD (abst) 290
once weekly vs. thrice weekly, HD (abst) 296
pharmacokinetics (abst) 614
progenitor cells, CRF (abst) 282
RBC immune deficiency, uremia (abst) 616
vascular responsiveness, norepinephrine, RF 806
Red blood cells
immune deficiency, uremia, rHuEPO (abst) 616
oxalate transmembrane flux, nephrolithiasis 1549
polyamines, CRF, HD (abst) 615
Rejection. See also Immunosuppression
acute, ANP and kallikrein immunolocalization (abst) . . . 909
acute, clinical analysis (abst) 638
acute, ICAM-1 (abst) 293
acute, impact on chronic rejection (abst) 638
acute, increased MAP-I excretion (abst) 1369
acute, PBMC, TNF-a (abst) 639
acute, racial factors, graft survival 1592
Banif criteria, histologic diagnosis on biopsy (abst) . . . . 1368
CD4/CD8, IL-2, IL-2r, TNF-c as indicators (abst) 640
chronic, clinical trial design 52:S-116
chronic, isoprenoids and Ras protein 52:S-34
chronic, predicted by AUCC 251
clinical predictors of 52:S-90
cytokine gene expression in renal grafts 1504
differential diagnosis, CsA toxicity 52:S-68
FK506, preliminary experience with (abst) 908
molecular mechanisms 52:S-7
PAF role, rats 337
tubulointerstitial, vascular, tissue antigens 52:S-16
Renal arterioles, smooth muscle phenotypes, MHC
isoforms 372
Renal artery stenosis
RVH, balloon-expandable stent implantation (abst) ... 1368
spiral-CT angiography 1332
Renal biopsy. See Biopsy, renal
Renal blood flow (RBF)
hippurate clearance measures 1617
NO regulates (abst) 303
Renal cell carcinoma, APKD (abst) 300
Renal disease
adhesion molecules in 1687
ANCA, clinicohistology (abst)
astragalus root effects, cytokines (abst)
atheroembolic, ARF (abst)
BP and progression of nephrosclerosis
clinicopathology, PAN (abst)
detecting TNF receptors (abst)




NO synthesis blockage induces hypertension (abst)
non-neoplastic, differentiation antigens, fibrosis (abst)
Renal duplex sonography, RVD, older patients
beginning dialysis
Renal failure. See also Acute renal failure; Chronic renal
failure
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CT scan diagnoses analgesic nephropathy 1316
hemoglobin carbamylation 1605
LDL oxidation 227
lipoprotein lipase, hypertriglyceridemia 779
oxalosis-unrelated, bony oxalate 182
rHuEPO, vascular responsiveness, hypertension 806
terminal, HLA antigen distribution (abst) 1675
Renal fibroblast heterogeneity 50:S-33
Renal function
acute/chronic stress, arterial pressure, dietary Na
(abst) 612
AGEs effects in rats (abst) 627
arterial hypertension, epidemiology study (abst) 274
central All effects mediated by area postrema (abst) . . . 611
cold ischemia, cytoprotective agents (abst) 1680
in heroin addiction (abst) 620
histological changes, normoalbuminuric IDDM (abst). . . 276
NG-nitro-L-arginine, blood pressure, rats (abst) 613
osmotic regulation of betaine 1714
residual, chronic HD (abst) 286
secretory phospholipase A2 release, OKT3 treatment
(abst) 1369
sequential biopsies, IDDM 1920
Renal functional reserve (RFR)
children, renal disease, serum creatinine (abst) 1676
determined by radiopharmaceuticals (abst) 906
Renal growth
early diabetes-related, renal SPARC mRNA 1216
IGF-1, PTH, high protein diet 33
Renal hemodynamics
area postrema, Na balance, DOCA hypertension
(abst) 613
captopril, proteinuria (abst) 275
glomerular permeability, Ang II (abst) 299
opioid role, response to water immersion 860
tertatolol and atenolol, with CsA (abst) 1365
Renal hypertrophy
rhubarb (Chinese medicine), STZ-diabetic rats (abst). . . 628
role of polyaniines 731
TGF-13, diabetic kidney and 51:S-34
Renal injury
nucleotides and renal wound healing 85
organophosphorus pesticides poisoning (abst) 637
post-traumatic asphyxia, crushing chest syndrome
(abst) 635
radiation sickness (abst) 636
Renal insufficiency, acute, lupus nephritis (abst) 621
Renal ischemia. See Ischemia, renal
Renal mass
experimental transplantation, late outcome 52:S-43
reduced, long-term effects in humans 814
reduced, pregnancy, glomerular hemodynamics, rats 39
Renal morphology, IDDM, normal and high GFR (abst). . 276
Renal plasma flow (RPF), evaluation with SPECT (abst). . 609
Renal replacement therapy (RRT)
diabetes, sixteen-year study (abst) 283
renovascular disease, older patients 171
Renal resistance index, renovascular hypertension 1611
Renal tissue, endogenous ACEi present (abst) 1366
Renal tumors
dialysis patients (abst) 288
flow cytometric DNA ploidy, acquired PKD (abst) 289
Renal uptake, 18-mer phosphorothioate oligonucleotide. . 1226
Renal vascular niB-adrenergic receptors 1412
Renin
CsA impairs conversion (abst) 295
inactive plasma, activity measurement, HD (abst) 642
Renin-angiotensin system (RAS)
dietary protein, chronic rejection 52:S-102
polymorphisms with microalbuminuria in NIDDM . . . . 1898
sequential changes in mRNA, acute UUO 1247
Renovascular disease (RVD)
hypertension, balloon-expandable stent implantation
(abst) 1368
hypertension, resistance index after captopril 1611
hypertension, treatment with PTRA 1927
older patients beginning dialysis 171
Reperfusion
allopurinol, SOD, post-ischemia (abst) 632
apoptosis during, post-renal ischemia (abst) 610
apoptosis in tubular repair, post-ischemia (abst) 631
L-Arg, renal ischemia (abst) 633
Residual renal function (RRF), chronic hemodialysis
(abst) 286
RGD peptides, synthetic, therapeutic role in ARF 1375
Rheum (Chinese medicine), captopril, CRF progression
(abst) 617
Rhubarb (Chinese medicine)
glomerular morphology, STZ-diabetic rats (abst) 627
renal hypertrophy, STZ-diabetic rats (abst) 628
Rifampicin
causes ARF (abst) 1678
staphylococcal infection, CAPD (abst) 296
ROMK in distal nephron, ATP-regulated in K channels. 1010
S
Salt intake
post-ischemic kidney regeneration (abst) 631
stress, arterial pressure, renal function (abst) 612
Scanning force microscopy, dialyzer membrane inner
surfaces (abst) 296
Screening, acquired cystic kidney disease 207
SDS PAGE predicts steroid responsiveness, NS (abst) .. . . 904
Secondary hyperparathyroidism
biochemical bone markers (abst) 279
calcitriol, pulse iv. vs. oral, HD (abst) 296
calcitriol, single weekly iv. bolus (abst) 278
calcitriol alters PTH-calcium relation (abst) 280
calcium-regulated PTH release 1553
chronic renal failure (abst) 617
control with low Ca bath, without calcitriol (abst) 281
delayed renal allograft function (abst) 294
endogenous calcitonin, CRF (abst) 280
endothelial factors, ESRD (abst) 279
high dose 1,25(OH)2D3 (abst) 280
low calcium dialysate, PTH (abst) 278
total parathyroidectomy with autograft (abst) 279
Selectivity index (SI)
diurnal variation, IDDM 1559
predicting steroid responsiveness, NS (abst) 904
Sepsis. See Infection
Severe combined immunodeficiency, human monoclonal
IgG anti-DNA antibodies 705
Simple renal cystic disease, prevalence/clinicomorphology
(abst) 1675
Simvastatin, diet, idiopathic membranous nephropathy
(abst) 904
Single photon emission computerized tomography
(SPECT), GFR, renal plasma flow (abst) 609
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Smooth muscle phenotypes of renal arterioles 372
Smooth muscle tumors, X-linked Alport syndrome 1891
Sodium
low sodium peritoneal dialysate 1950
salt intake, post-ischemic regeneration (abst) 631
salt intake, stress, arterial pressure, renal function (abst) .. 612
Sodium balance, area postrema, renal hemodynamics,
DOCA hypertension (abst) 613
Sodium channels
cross-talk, K channels, tight epithelia 1191
epithelial, aldosterone modulation 965
epithelial, expression cloning 950
epithelial, regulation, actin cytoskeleton 970
renal, regulation, single channel properties 941
topology of amiloride binding proteins 956
Sodium loading, renal mobilization of dopamine, EH
(abst) 609
Sodium transport
altered, body mass, LVH, EH (abst) 273
altered, familiar aggregation, HLA system,
hypertension (abst) 273
altered, metabolic alterations, EH (abst) 273
Sorbinil, osmolyte changes, galactosemia 344
SPARC gene expression, renal enlargement, DM 1216
Spiral-CT angiography, renal artery stenosis 1332
Splenic mechanisms, ROS-mediated glomerular injury
(abst) 600
Standard peritoneal permeability analysis 866
Staphylococcal infection, CAPD, rifampicin (abst) 296
Stents, balloon-expandable, RVH, atherosclerotic ostial
RAS (abst) 1368
Steroid-resistant idiopathic nephrotic syndrome
children, i.v. albumin (abst) 587
CsA treatment (abst) 277
sequential immunosuppression (abst) 294
Steroids
with CsA and azathioprine, chronic allograft failure . 52:S-94
with CsA and azzathioprine, methotrexate, SLE and
LN (abst) 623
HIV-associated nephropathy (abst) 1366
responsiveness predictors, NS (abst) 904
Stones, renal. See Calculi, urinary
Stress, acute/chronic, arterial pressure, renal function,
dietary Na (abst) 612
Stretch-activated ion channels 1134
Subclavian vein
catheterization, venogram abnormalities (abst) 289
obstruction, nuclear venography with technetium (abst) . . . 905
thrombosis, coagulation profiles, CRF (abst) 905
Superoxide dismutase (SOD)
MnSOD regulation, glomerular EC 354
renal ischemia, reperfusion, allopurinol (abst) 632
Systemic lupus erythematosus (SLE)
antiphospholipids and hemodialysis 794
corticosteroids with methotrexate, azathioprine, CsA
(abst) 623
human monoclonal IgG anti-DNA antibodies 705
nephritis, apoptosis, nucleosomes 666
serum erythropoietin level (abst) 625
serum soluble TNF receptor, TNF-a (abst) 625
Systemic vasculitis, ANCA as markers (abst) 278
T
T lymphocytes
HgCI2-induced activation, intracellular redox status
(abst) 1364
minimal change NS (abst) 599
Technetium, nuclear venography, subclavian vein
obstruction (abst) 905
Tertatolol, renal/systemic hemodynamics with CsA (abst). 1365
Thick ascending limb (TAL), NHE-3 expression, rat
kidney 1206
3-D analysis/reconstruction
EGFr, tubular cells, collagen-TV, IL-8 mRNA (abst). . . . 647
glomerular morphology in ablation 155
mesangial cells, LSC microscope (abst) 600
Thrombolic microangiopathy, lupus nephritis (abst) 621
Thrombosis
antiphospholipids and hemodialysis 794
subclavian vein, coagulation profiles, CRF (abst) 905
Thrombospondin I expression, PDGF, bFGF, GN 1837
Thromboxane
fibronectin synthesis, PKC, TGF-/3, MC 422
synthase expression in macrophages 1344
Thromboxane A2, post-ischemic ARF, prostacyclin 1577
Thromboxane B2, glomerular synthesis, CsA (abst) 294
Thymus immuno-suppressor essence, infantile purpura
GN (abst) 618
Thyroid, hypothalamic-pituitary axis, uremia (abst) 1678
Toxicity. See Nephrotoxicity
Transcriptional control, renal iNOS, NF-KB 674
Transfemoral renal biopsy with forceps (abst) 275
Transforming growth factor-3 (TGF-p)
AGEs, MC collagen production 111
Ang II, obstructive nephropathy 1233
complement inhibition by human MC (abst) 606
CsA nephrotoxicity 1487
diabetic GS, renal hypertrophy 5 1:S-34
fibronectin synthesis in tubular EC 1810
high glucose media, cultured MC (abst) 629
high glucose media enhances MvlLu, MC (abst) 628
human IgA glomerulonephritis 1530
parallel inhibitory signaling, phorbol esters 738
PKC, fibronectin synthesis, MC 422
PT expression, Ang II, c-mas oncogene 1818
transfer into the glomerulus 1747
Transforming growth factor-p 1 (TGF-131)
mRNA expression, lovastatin, diabetic nephropathy . 5 1:S-61
sense/antisense expression vector transfected cells
(abst) 604
Transgenic rescue of mouse GS 80
Transplantation. See also Allografts; Donor kidneys;
Rejection
Banif classification, clinicopathology (abst) 910
CMV antigenemia assay (abst) 639
diabetes, sixteen-year study (abst) 283
diabetic patient, management of, Nephrology Forum . . 1660
diltiazem and CsA (abst) 1678
dyslipidemia, carnitine deficiency (abst) 286
enalapril treatment, erythrocytosis (abst) 293
erythrocytosis, enalapril treatment (abst) 1678
experimental, renal mass, chronic allograft failure. . . 52:S-43
extracutaneous Kaposi sarcoma, immunosuppression
(abst) 301
HLA-DR antigen expression changes (abst) 639
HLA matching (abst) 295
hyperlipidemia, epidemiology (abst) 294
India, evaluated (abst) 1681
India, risks/ethical aspects (abst) 1679
Kaposi's sarcoma (abst), 1677 1679
ketoconazole and cyclosporine (abst) 908
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LDL oxidation . 227
liver, CRF (abst) 293
malignant tumors after (abst) 302
mortality, analysis of causes (abst) 638
mycophenolate mofetil 52:S-98
nocardiosis outbreak (abst) 909
pancreas, CsA nephrotoxicity 489
patient selection, evaluation for (abst) 907
postischemic injury, Na7K-ATPase 1308
pregnancy after (abst) 909
proteinuria quantitation of (abst) 302
racial factors, rejection, graft survival 1592
renal function, dopamine and anisodamine (abst) 638
S. Africa, attitudes towards (abst) 909
Traumatic asphyxia, renal injury after (abst) 635
Trimethoprim-sulfamethoxazole, Wegener's
granulomatosis (abst) 1367
Tripchlorolide prolongs cardiac allograft (abst), 639 640
Tubular cells, 3-D reconstruction, collagen-IV, EGFr,
IL-8 mRNA (abst) 647
Tubular interstitial alterations, NIDDM nephropathy
(abst) 629
Tubular necrosis, acute experimental, EGF (abst) 631




Tubular regeneration, ET-1 mediated autocrine growth
loop 390
Tubuloglomerular feedback, responsiveness, NO and
Ang H 1406
Tubulointerstitial disease, urinary retinolbinding protein
(abst) 645
Tubulointerstitial injury, macrophages in anti-GBM GN... 753
Tubulointerstitial nephritis, leukocytes, primary MCGN
(abst) 908
Tubulointerstitial rejection, tissue antigens 52:S-16
Tubulointerstitial volume alterations, lupus nephritis
(abst) 622
Tubulopathy, myeloma, protease resistance, Ig light
chains 72
Tumor necrosis factor-a (TNF-a)
acute rejection, PBMC (abst) 639
CDI8 in PMN interaction with GBM 698
glomerular endothelial injury, LPS (abst) 302
glomerular mesangial cells (abst) 604
ICAM-1, GN (abst) 596
as indicator, acute allograft rejection (abst) 640
serum levels, SLE and LN 625
stimulates MC secretion (abst) 595
Tumor necrosis factor (TNF)
levels, acetate-free HD (abst) 642
receptor detection, renal disease (abst) 597
receptor modulates antibody-mediated glomerular
injury 1738
receptor serum levels, SLE and LN 625
Tumoral calcifications, HD, bone histopathology (abst) ... 278
Tyrosine kinase inhibitors 52:S-28
U
Ultrafiltration
improved in CCPD with glucose polymer (abst) 1368
low sodium peritoneal dialysate 1950
Ultrasonography, high-resolution B-mode, atherosclerosis
in uremia 820
Uninephrectomy
llp-OHSD activity, remaining kidney (abst) 297
physiologic changes, plasma/urine ET-1, humans (abst). . 303
United Network of Organ Sharing, chronic allograft
failure data 52:S-53
Urate-anion exchange, BBM vesicles, nicotinate, orotate
(abst) 297
Urea, hemoglobin-oxygen affinity, uremic anemia 827
Urea kinetic modeling (Kt/V)
accuracy of equilibrated measurements 832
accuracy of urea removal 785
in CAPD by different estimations of V 563
dialysate temperature, central hemodynamics 237
urea rebound, post-dialysis (abst) 285
urea rebound, residual GFR (abst) 285
Urea reduction rate (URR) measures HD adequacy
(abst) 287
Uremia
adrenogens for anemia (abst) 283
atherosclerosis, ultrasonography 820
calcitriol alters PTH-calcium relation (abst) 280
dyspepsia, helicobacter pylon antibodies (abst) 1677
fibronectin, opsonin receptor expression, PMC (abst)... 615
hypothalamic-pituitary-thyroid axis (abst) 1678
oxidants in uremic plasma, detection 199
serum Ca modifies set-point, HD (abst) 280
Ureters
bilharzial strictures and RF (abst) 907
UUO, sequential changes, RAS mRNA expression.... 1247
Urinalysis
disposable napkins, accuracy (abst) 1679
routine, as screening test for UT! (abst) 300
Urinary calculi. See Calculi, urinary
Urinary excretion
albumin, diurnal variation, IDDM 1559
nitrite + nitrate, renal vascular NO production 1272
Urinary proteins
early diabetic nephropathy (abst) 628
SDS PAGE predicts steroid responsiveness, NS (abst) .. 904
Urinary prothrombin fragment 1, calcium oxalate crystals
(ahst) 910
Urinary retinolbinding protein (RBP)
proximal tubular function in neonates (abst) 645
tubulointerstitial disease (abst) 645
Urinary tract abnormalities, by fetal ultrasonography
(abst) 1676
Urinary tract infection (UT!)
children, inactivated uropathogenic bacterial vaccine
(abst) 1677
children, P fimbria (+) E. coli (abst) 1676
urinalysis as screening test (abst) 300
Urine collection without catheters (abst) 1367
V
V2 receptors
defects, vasoactive effects of AVP (abst) 1364
gene mutations, nephrogenic DI 554
nonpeptide antagonist, aquaresis, hydropenic humans.. . 220
Vaccination
cholera immunization, IgAN (abst) 1364
inactivated uropathogenic bacteria, children, UTI
(abst) 1677
Vancomycin, catheter-related sepsis, HD (abst) 289
Vascular access
blood flow measurement, dilution technique 244
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catheter-related sepsis, vancomycin (abst) 289
diabetic, non-diabetic patients (abst) 290
dual jugular vein catheterization (abst) 286
flow measurement by dilution technique, HD 244
long-term coumarins, vascular prosthesis, HD (abst). . . . 296
Lp(a) levels, chronic HD (abst) 283
malfunction, diagnosis/evaluation (abst) 283
monomelic ischemic neuropathy (abst) 291
thrombosis, antiphospholipids and HD 794
thrombosis, subclavian, coagulation profiles, CRF
(abst) 905
venography, subclavian (abst) 905
venography, subclavian and jugular HD catheters
(abst) 289
Vascular adhesion molecule-i (VCAM-1)
expression, lupus/crescentic nephritis (abst) 597
ICAM-i, lupus nephritis, MPGN (abst) 596
Vascular calcifications, endothelial factors, ESRD,
secondary HPT (abst) 279
Vascular rejection, tissue antigens 52:S-16
Vascular relaxation, heparin-induced 1508
Vascular responsiveness and rHuEPO 806
Vascular smooth muscle cells (VSMC), CsA
nephropathy, ET supernatant, MC (abst) 633
Vasculitis
ANCA significance (abst) 619
PR3-ANCA, PiZ gene of a1-AT 844
systemic, ANCA as markers (abst) 278
Venography
abnormalities, subclavian and jugular HD catheters
(abst) 289
nuclear with technetium (abst) 905
Villin in ATP depletion with actin 1828
Vitamin D3
1,25(OH)2D3, as parathyroidectomy alternative (abst). . . 280
children, NS, calcium agents/metabolism (abst) 590
reduction Ca concentration, HD (abst) 280
Voltage gated K channels 1031
w
Water channels
ADH and transport in amphibian epithelia 1088
aquaporin, in the kidney 1057
aquaporin 2 gene defect, DI (abst) 300
of collecting duct 1082
structure and function 1069
Water immersion, opioid role in response to 860
Wegener's granulomatosis
co-trimoxazole prevents relapses (abst) 1367
decreased frequency of HLA-DR13DR6 801
Wilm's tumor, PDGF A-chain expression in kidneys 146
x
Xenograft lesions, leflunomide and CsA 52:S-28
